Knockdown of FOXE1 in CRC cell lines HT29 and SW480 by shRNA remarkably increased cell proliferation, colony formation and promoted glucose consumption, as well as lactate production through the FOXE1/HK2 axis, indicating that targeting FOXE1 could be a promising therapeutic option for CRC [261]. Here, FOXE1 is linked to colorectal carcinoma.